Newron FDA Clinical Hold Continues: Evenamide Safety Flag
FDA keeps its hold on Newron US schizophrenia trial, citing a possible cardiac safety signal for evenamide. What is known and what comes next.
FDA keeps its hold on Newron US schizophrenia trial, citing a possible cardiac safety signal for evenamide. What is known and what comes next.
The FDA told a federal court its mifepristone safety review will run into 2027, with a report due by March. Timeline, context and what changes now.
Argenx stops its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease for futility; shares fell about 16%. What it means for the pipeline.
Will cancer drugs get cheaper? India caps trade margins on non-scheduled cancer medicines at 30% of MRP; some prices may fall up to 70%.
Supreme Court directs the Centre to form a committee on pharma freebies to doctors in India, as the UCPMP marketing code faces an enforcement test.
FDA approves Novartis Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism. RemIND Phase III data, safety and what patients should know.
Indian drug panel recommends a red warning on cough syrup labels for children under 4 and a ban on child imagery. What changes, the legal steps and advice.
Lupin launches Formoflo-G, a fixed-dose triple-combination MDI for COPD in India. What it contains, who it is for, what is unknown and the market context.
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.
Epcoritamab plus R-CHOP met the primary PFS endpoint in the Phase 3 EPCORE DLBCL-2 trial, cutting progression risk 51%. What it means for DLBCL.